All In MedTech

Device Trial Radar · NCT06420245

Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management

A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Nov 2026

Study completion Jul 2027

Sponsor

Lead sponsor
Legacy Medical ConsultantsNot on our public-company list
Sponsor type
Industry
First posted
May 17, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot ulcers. The study aims to determine the incidence of complete wound closure at the end of 12 weeks of treatment. Researchers will compare the outcomes between a group of people treated with standard wound care and another group treated with standard wound care in addition to the amniotic membrane allograft to see if the amniotic membrane allograft improves wound healing. During the study, participants will visit their doctor weekly over a 12 week period, which is standard for diabetic foot ulcer treatment procedures, and fill out a questionnaire measuring quality of life.

Conditions

  • Diabetic Foot Ulcer

Interventions

  • Orion TM Amniotic Membrane AllograftDevice

    The intervention is a sterile allograft made from dehydrated extracellular matrix, designed to promote wound healing by providing a reliable and protective wound covering. Amniotic membranes are hypothesized to promote healing in open wounds by serving as a scaffold to support native tissue ingrowth, encouraging angiogenesis, and limiting microbial spread.

  • Standard of Care (SOC)Procedure

    Standard wound care entails surgical debridement as needed to remove all non-viable tissue, screening for infection and probing of the wound for bone, weekly application of a collagen alginate primary dressing, and off-loading using a removable diabetic offloading cam-walker or total contact cast.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Complete Wound ClosureTime frame: starting from randomization until last visit of the 12-week wound management period

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • DPMG

    Palm Springs, California

  • Center for Clinical Research Inc.

    San Francisco, California

  • ILD Research Center

    Vista, California

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.